Industrial Research and Development Incentives Act 1976
RepealedCTH
This Act has been repealed and is no longer in force. It is retained for historical reference.
Jurisdiction
Commonwealth
Act Number
85 of 1976
Collection
act
Plain English Summary
8/10 complexity
What this law does, mechanically
Establishes a scheme of Commonwealth financial assistance (grants and advances) for industrial research and development (R&D) carried out in Australia by companies or on their behalf. It creates two main grant streams: commencement grants (Division 1, Part III) and project grants (Division 2, Part III) (see sections 23 and 30).
Defines precisely who can claim and what counts as eligible activity and eligible expenditure. Core definitions and limits are in section 4 (notably definitions of "eligible company", "eligible expenditure" and the component categories such as eligible salary, plant, prototype and contract expenditure) and section 5 (rules for "related" companies).
Gives the Board (the Australian Industrial Research and Development Incentives Board) power to approve research organisations, recognise professional institutes and approve individual employees for the purpose of counting some costs as eligible (see sections 6 and 7). The Board also decides applications, subject to this Act and any Ministerial directions (see sections 23(2), 30(1)).
Sets monetary and temporal limits on grants and allocates decision and reporting roles: caps per grant-year and per-company aggregates (sections 23, 24, 32(4), 32(6)), time-limited grant years and project end-dates (see definitions of "grant year" in section 4 and project restrictions in section 32(3)), and annual Minister/Board allocation steps (section 31).
Builds in compliance, repayment and anti-abuse mechanisms: applicants must apply in approved form and submit books/records on request (section 34); advances require security and are repayable if the grant does not materialise (section 35); the Board can recover overpayments where false or misleading material was used (section 38); and the Board can disregard or adjust expenditure it regards as an attempt to abuse the Act (section 29).
Sourced from the Federal Register of Legislation (legislation.gov.au), CC BY 4.0.
Requires companies to give written undertakings to exploit results commercially and for the benefit of the Australian economy as a condition of receiving grants (sections 27 and 32A).
Requires parliamentary appropriation for payment of grants (section 36) and annual reporting by the Board, including the names of companies that received grants and amounts (section 40).
Stated policy purpose and how the mechanics relate to it
The Act states its object as "to promote the development and improve the efficiency of Australian industry by encouraging industrial research and development in Australia in matters relating to science and technology" (section 3). That is an explicit policy claim in the text.
Mechanically, the Act attempts to realise that objective by lowering the private cost of carrying out certain R&D through direct Commonwealth financial assistance (commencement and project grants) (see sections 23 and 30). The assistance is conditional: eligibility rules (section 4), approval gates (sections 6–7), caps and aggregation rules (sections 24, 32(6)), reporting and exploitation undertakings (sections 27, 32A), and checks against other Commonwealth assistance (sections 28 and 32B).
Testing the policy claim against concrete trade-offs and operational facts in the Act
Who pays: payments are made from moneys specifically appropriated by Parliament for the Act (s.36). The Act therefore transforms Parliamentary appropriation into transfers to eligible firms, subject to the Board's authorisation and available appropriation (s.29A, s.36).
Who decides: the Board has primary decision authority (approvals, eligibility opinions, grant authorisations) and may be subject to Ministerial directions (see references at s.23(2), s.30(1) and the allocation process in s.31). The Board also holds fact‑finding and evaluative discretions (for example, the Board forms opinions about what is "reasonable charge" for contract work, s.4 definition of eligible contract expenditure, and may determine sale values on disposal, s.4(7)).
Incentives and private behaviour: by subsidising eligible categories of R&D expenditure (salary, plant, prototype, technical information, certain contract work), the Act reduces the marginal cost to an eligible company of carrying out R&D that fits the statutory definitions (s.4, s.23). The Act conditions support on exploiting results commercially and for Australian economic benefit (s.27, s.32A), which imposes a behavioural requirement on beneficiaries.
Compliance burden on companies: applicants must use Board-approved forms and may be required to produce books, records and further information the Board specifies (s.34(2), (3), (4)). Some documents submitted may need statutory declaration if the regulations require it (s.42(b)). Timing rules restrict when late applications are treated as made (s.34(3A), s.34A). Advances require "adequate security" (s.35(1B)). These are concrete administrative and administrative‑law compliance costs for firms.
Bureaucratic discretion and safeguards: the Board has multiple discretions — to approve research organisations and employees (s.6, s.7), to determine reasonable charges and values (s.4 definitions), to reduce grants where the company has received other Commonwealth assistance (s.28, s.32B), to disregard or adjust expenditure to prevent abuse (s.29), and to refuse to consider or delay applications pending additional information (s.34(4)). The Act also requires publication of names and amounts in the Board's annual report (s.40(2)(b)), which supplies a transparency mechanism.
Limits and allocation rules that shape who benefits: the Act limits how many years a company can receive commencement grants (s.25), caps per-company aggregates of grants (s.24), and imposes per-year caps on amounts attributable to a company across project agreements (s.32(6)). The Act aggregates related companies by shareholding rules (s.5) so groups of related entities cannot bypass per-company caps. The Minister also specifies total amounts available for project grants each year (s.31), creating an explicit budget constraint and prioritisation mechanism.
Risk of concentrated benefit and transparency: the scheme channels public funds to selected companies; the Act requires the Board to report recipient names and grant amounts annually (s.40(2)(b)), making the concentration of benefits public information.
Enforcement and repayment: advances and grants can be recovered if grants do not eventuate or were obtained on false or misleading material (s.35(2), s.38). Project agreements may include express repayment provisions for breaches (s.33).
Practical effects on industry choices (mechanisms rather than value judgements)
Firms that satisfy the definitions and approval gates can lower their effective R&D cost for eligible activities (s.4, s.23, s.30).
To qualify for assistance on contract work, the research organisation must be an approved research organization at the time the work is carried out (s.4 definition of eligible contract expenditure; s.6).
The Board’s approval of particular employees as "approved employees" may enable salary costs to be counted as eligible when employees lack formal professional qualifications (s.7).
Firms must be prepared to provide records and meet undertakings to exploit results if they want grant payments (s.27, s.34(4), s.40).
Implementation risks and opportunity costs signalled in the Act
Budgetary constraint: payment of grants is conditional on Parliamentary appropriation (s.36) and the Board must not authorise grants or advances beyond moneys available (s.29A, s.31). That creates an opportunity cost (public funds committed to this scheme are not available for other programmes).
Administrative workload: the Act gives the Board power to demand information and to exercise multiple evaluative discretions (s.34(4), s.29, s.28, s.32B). That implies administrative effort for both the Board and applicants.
Time limits and transitional rules: the Act defines a limited set of "grant years" (s.4 definition) and restricts project grants to not extend beyond a particular year (s.32(3)), which sets a calendar boundary for eligibility and planning.
Commencement grants: s.23, with caps and eligibility conditions; maximum aggregates: s.24; years limit: s.25
Project grants and limits: s.30, s.31, s.32, s.32A
Application and compliance rules: s.34, s.34A, s.35
Anti‑abuse and adjustment for other Commonwealth assistance: s.29, s.28, s.32B
Recovery, reporting and appropriation: s.35(2), s.38, s.40, s.36
Regulation-making power: s.42
Overall: the Act creates a time‑bounded, administratively mediated subsidy scheme for specified kinds of industrial R&D. The Board administers eligibility, approvals and payments within statutory caps and Ministerial allocation limits. Companies bear application and record‑keeping obligations, must comply with exploitation undertakings, and face repayment or adjustment where payments were assisted by other Commonwealth funds or obtained through false or misleading material (see the cited sections above).